Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6ZSZ5
UPID:
ARHGI_HUMAN
Alternative names:
114 kDa Rho-specific guanine nucleotide exchange factor; Septin-associated RhoGEF
Alternative UPACC:
Q6ZSZ5; A8MV62; B5ME81; I3L1I5; O60274; Q6DD92
Background:
Rho guanine nucleotide exchange factor 18, also known as a 114 kDa Rho-specific guanine nucleotide exchange factor or Septin-associated RhoGEF, plays a pivotal role in cellular processes. It acts as a guanine nucleotide exchange factor for RhoA GTPases, promoting actin stress fiber formation, and for RAC1, enhancing reactive oxygen species production. This protein does not influence CDC42 but is activated by G protein beta-gamma subunits, integrating effects of LPA and other GPCR agonists on cell morphology and ROS generation.
Therapeutic significance:
Rho guanine nucleotide exchange factor 18 is implicated in Retinitis pigmentosa 78, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field. Understanding the role of this protein could open doors to potential therapeutic strategies for this autosomal recessive disease.